Verastem (NASDAQ:VSTM) reported a global licensing agreement with Chugai Pharmaceutical (OTCPK:CHGCF) to develop rights to RAF/MEK inhibitor CH5126766 for KRAS-mutant solid tumors.
Yesterday, shareholders made more than a 36% stock returns:
VSTM data by YCharts
In December, Citadel and Highbridge acquired shares. Those readers following our stock alerts knew about it. Today, we would not buy shares.
Disclosure: No Positions
Buy our 10 pages analysis for just $29!
Previous Financial Analysis:
# Equity Research Report: BANGI, Inc. (OTCMKTS: BNGI) Growing Through Acquisitions
# Lennox International (NYSE: LII): We Don’t Like The Accumulation Of Inventory